Eli Lilly and Company $LLY Shares Bought by Zullo Investment Group Inc.

Zullo Investment Group Inc. boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.4% in the 2nd quarter, Holdings Channel.com reports. The fund owned 1,649 shares of the company’s stock after buying an additional 85 shares during the quarter. Zullo Investment Group Inc.’s holdings in Eli Lilly and Company were worth $1,286,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. First Fiduciary Investment Counsel Inc. purchased a new position in shares of Eli Lilly and Company during the second quarter worth $390,000. Strengthening Families & Communities LLC boosted its position in shares of Eli Lilly and Company by 723.1% during the second quarter. Strengthening Families & Communities LLC now owns 107 shares of the company’s stock worth $88,000 after buying an additional 94 shares during the period. Strong Tower Advisory Services boosted its position in shares of Eli Lilly and Company by 3.9% during the second quarter. Strong Tower Advisory Services now owns 10,621 shares of the company’s stock worth $8,279,000 after buying an additional 397 shares during the period. PDS Planning Inc boosted its position in shares of Eli Lilly and Company by 9.8% during the second quarter. PDS Planning Inc now owns 7,382 shares of the company’s stock worth $5,754,000 after buying an additional 660 shares during the period. Finally, Gunderson Capital Management Inc. boosted its position in shares of Eli Lilly and Company by 960.0% during the second quarter. Gunderson Capital Management Inc. now owns 2,703 shares of the company’s stock worth $2,107,000 after buying an additional 2,448 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on LLY. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Guggenheim raised their price target on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a “buy” rating in a research report on Wednesday. Morgan Stanley lowered their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research note on Friday, October 3rd. Finally, HSBC boosted their target price on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $948.56.

Eli Lilly and Company Trading Down 2.6%

LLY opened at $833.08 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The stock has a market capitalization of $788.47 billion, a price-to-earnings ratio of 54.45, a PEG ratio of 1.19 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The business has a fifty day moving average price of $742.42 and a 200 day moving average price of $766.36.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same period in the previous year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger purchased 117 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock worth $2,894,841 over the last three months. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.